Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II single-arm study of utidelone injection in recurrent or metastatic HER2-negative breast cancer
ChiCTR2200056534Phase 2Not yet recruiting
- Sponsor
- Shandong Cancer Hospital
- Start
- Aug 2022
- Modality
- Allosteric Modulators → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of utidelone in breast cancer, sponsored by Shandong Cancer Hospital. Primary endpoint: Progression-free survival. Planned start Aug 2022; status: not yet recruiting.
02
Drugs
utidelone
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2200056534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056534.